Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 371

1.

Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.

Lavezzi SM, de Jong J, Neyens M, Cramer P, Demirkan F, Fraser G, Bartlett N, Dilhuydy MS, Loscertales J, Avigdor A, Rule S, Samoilova O, Goy A, Ganguly S, Salman M, Howes A, Mahler M, De Nicolao G, Poggesi I.

Pharm Res. 2019 May 1;36(7):93. doi: 10.1007/s11095-019-2605-8.

PMID:
31044267
2.

Global donor and acceptor splicing site kinetics in human cells.

Wachutka L, Caizzi L, Gagneur J, Cramer P.

Elife. 2019 Apr 26;8. pii: e45056. doi: 10.7554/eLife.45056. [Epub ahead of print]

3.

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.

Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O'Brien SM, Stilgenbauer S.

J Clin Oncol. 2019 Apr 17:JCO1801460. doi: 10.1200/JCO.18.01460. [Epub ahead of print]

PMID:
30995176
4.

MYC Recruits SPT5 to RNA Polymerase II to Promote Processive Transcription Elongation.

Baluapuri A, Hofstetter J, Dudvarski Stankovic N, Endres T, Bhandare P, Vos SM, Adhikari B, Schwarz JD, Narain A, Vogt M, Wang SY, Düster R, Jung LA, Vanselow JT, Wiegering A, Geyer M, Maric HM, Gallant P, Walz S, Schlosser A, Cramer P, Eilers M, Wolf E.

Mol Cell. 2019 May 16;74(4):674-687.e11. doi: 10.1016/j.molcel.2019.02.031. Epub 2019 Mar 27.

5.

Yeast mitochondrial protein Pet111p binds directly to two distinct targets in COX2 mRNA, suggesting a mechanism of translational activation.

Jones JL, Hofmann KB, Cowan AT, Temiakov D, Cramer P, Anikin M.

J Biol Chem. 2019 May 3;294(18):7528-7536. doi: 10.1074/jbc.RA118.005355. Epub 2019 Mar 25.

PMID:
30910813
6.

Misclassification of bicuspid aortic valves is common and varies by imaging modality and patient characteristics.

Cramer PM, Prakash SK.

Echocardiography. 2019 Apr;36(4):761-765. doi: 10.1111/echo.14295. Epub 2019 Mar 4.

PMID:
30834578
7.

Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.

Al-Sawaf O, Herling CD, Holtick U, Scheid C, Cramer P, Sasse S, von Tresckow B, Tuchscherer A, Fischer K, Eichhorst B, Hallek M, Frenzel LP.

Haematologica. 2019 May;104(5):e224-e226. doi: 10.3324/haematol.2018.212837. Epub 2019 Feb 21. No abstract available.

8.

Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies.

Burger JA, Cramer P, Barr PM, Dilhuydy MS, Mato A, Byrd JC, Chang S, Graef T, Lin T, Tedeschi A.

Br J Haematol. 2019 Feb 10. doi: 10.1111/bjh.15784. [Epub ahead of print] No abstract available.

PMID:
30739324
9.

Narcissism and Attachment: The Importance of Early Parenting.

Cramer P.

J Nerv Ment Dis. 2019 Feb;207(2):69-75. doi: 10.1097/NMD.0000000000000919.

PMID:
30672874
10.

Characterization of Two New Multidrug-Resistant Strains of Mycobacterium smegmatis: Tools for Routine In Vitro Screening of Novel Anti-Mycobacterial Agents.

Arthur PK, Amarh V, Cramer P, Arkaifie GB, Blessie EJS, Fuseini MS, Carilo I, Yeboah R, Asare L, Robertson BD.

Antibiotics (Basel). 2019 Jan 2;8(1). pii: E4. doi: 10.3390/antibiotics8010004.

11.

The Implication of Early Chromatin Changes in X Chromosome Inactivation.

Żylicz JJ, Bousard A, Žumer K, Dossin F, Mohammad E, da Rocha ST, Schwalb B, Syx L, Dingli F, Loew D, Cramer P, Heard E.

Cell. 2019 Jan 10;176(1-2):182-197.e23. doi: 10.1016/j.cell.2018.11.041. Epub 2018 Dec 27.

12.

Structure of transcribing RNA polymerase II-nucleosome complex.

Farnung L, Vos SM, Cramer P.

Nat Commun. 2018 Dec 21;9(1):5432. doi: 10.1038/s41467-018-07870-y.

13.

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.

von Tresckow J, Cramer P, Bahlo J, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Illmer T, Klaproth H, Estenfelder S, Ritgen M, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Böttcher S, Eichhorst BF, Hallek M.

Leukemia. 2019 May;33(5):1161-1172. doi: 10.1038/s41375-018-0313-8. Epub 2018 Dec 19.

PMID:
30568174
14.

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.

Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA.

Br J Haematol. 2019 Feb;184(4):558-569. doi: 10.1111/bjh.15690. Epub 2018 Dec 2.

PMID:
30506764
15.

Promoter Distortion and Opening in the RNA Polymerase II Cleft.

Dienemann C, Schwalb B, Schilbach S, Cramer P.

Mol Cell. 2019 Jan 3;73(1):97-106.e4. doi: 10.1016/j.molcel.2018.10.014. Epub 2018 Nov 21.

PMID:
30472190
16.

Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.

Al-Sawaf O, Bahlo J, Robrecht S, Fischer K, Herling CD, Hoechstetter M, Fink AM, von Tresckow J, Langerbeins P, Cramer P, Stilgenbauer S, Wendtner CM, Eichhorst B, Hallek M, Goede V.

Br J Haematol. 2018 Dec;183(5):727-735. doi: 10.1111/bjh.15604. Epub 2018 Nov 21.

PMID:
30460980
17.

Neuron-specific inactivation of Wt1 alters locomotion in mice and changes interneuron composition in the spinal cord.

Schnerwitzki D, Perry S, Ivanova A, Caixeta FV, Cramer P, Günther S, Weber K, Tafreshiha A, Becker L, Vargas Panesso IL, Klopstock T, Hrabe de Angelis M, Schmidt M, Kullander K, Englert C.

Life Sci Alliance. 2018 Aug 16;1(4):e201800106. doi: 10.26508/lsa.201800106. eCollection 2018 Aug.

18.

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Pavlovsky MA, Karlsson C, Hallek M, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Chanan-Khan A.

Leukemia. 2019 Apr;33(4):969-980. doi: 10.1038/s41375-018-0276-9. Epub 2018 Oct 12.

PMID:
30315239
19.

What Has Happened to Hysteria?

Cramer P.

J Nerv Ment Dis. 2018 Sep 25. doi: 10.1097/NMD.0000000000000850. [Epub ahead of print]

PMID:
30256330
20.

The interaction landscape between transcription factors and the nucleosome.

Zhu F, Farnung L, Kaasinen E, Sahu B, Yin Y, Wei B, Dodonova SO, Nitta KR, Morgunova E, Taipale M, Cramer P, Taipale J.

Nature. 2018 Oct;562(7725):76-81. doi: 10.1038/s41586-018-0549-5. Epub 2018 Sep 24.

21.

The APT complex is involved in non-coding RNA transcription and is distinct from CPF.

Lidschreiber M, Easter AD, Battaglia S, Rodríguez-Molina JB, Casañal A, Carminati M, Baejen C, Grzechnik P, Maier KC, Cramer P, Passmore LA.

Nucleic Acids Res. 2018 Nov 30;46(21):11528-11538. doi: 10.1093/nar/gky845.

22.

New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.

Pflug N, Cramer P, Robrecht S, Bahlo J, Westermann A, Fink AM, Schrader A, Mayer P, Oberbeck S, Seiler T, Zenz T, Dürig J, Kreuzer KA, Stilgenbauer S, Eichhorst B, Hallek M, Herling M, Hopfinger G.

Leuk Lymphoma. 2019 Mar;60(3):649-657. doi: 10.1080/10428194.2018.1488253. Epub 2018 Sep 20.

PMID:
30234404
23.

Structural basis of mitochondrial transcription.

Hillen HS, Temiakov D, Cramer P.

Nat Struct Mol Biol. 2018 Sep;25(9):754-765. doi: 10.1038/s41594-018-0122-9. Epub 2018 Sep 6. Review.

PMID:
30190598
24.

Structure of paused transcription complex Pol II-DSIF-NELF.

Vos SM, Farnung L, Urlaub H, Cramer P.

Nature. 2018 Aug;560(7720):601-606. doi: 10.1038/s41586-018-0442-2. Epub 2018 Aug 22.

25.

Structure of activated transcription complex Pol II-DSIF-PAF-SPT6.

Vos SM, Farnung L, Boehning M, Wigge C, Linden A, Urlaub H, Cramer P.

Nature. 2018 Aug;560(7720):607-612. doi: 10.1038/s41586-018-0440-4. Epub 2018 Aug 22.

PMID:
30135578
26.

RNA polymerase II clustering through carboxy-terminal domain phase separation.

Boehning M, Dugast-Darzacq C, Rankovic M, Hansen AS, Yu T, Marie-Nelly H, McSwiggen DT, Kokic G, Dailey GM, Cramer P, Darzacq X, Zweckstetter M.

Nat Struct Mol Biol. 2018 Sep;25(9):833-840. doi: 10.1038/s41594-018-0112-y. Epub 2018 Aug 20.

PMID:
30127355
27.

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.

Cramer P, von Tresckow J, Bahlo J, Robrecht S, Langerbeins P, Al-Sawaf O, Engelke A, Fink AM, Fischer K, Tausch E, Seiler T, Fischer von Weikersthal L, Hebart H, Kreuzer KA, Böttcher S, Ritgen M, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M.

Lancet Oncol. 2018 Sep;19(9):1215-1228. doi: 10.1016/S1470-2045(18)30414-5. Epub 2018 Aug 13.

PMID:
30115596
28.

RNA velocity of single cells.

La Manno G, Soldatov R, Zeisel A, Braun E, Hochgerner H, Petukhov V, Lidschreiber K, Kastriti ME, Lönnerberg P, Furlan A, Fan J, Borm LE, Liu Z, van Bruggen D, Guo J, He X, Barker R, Sundström E, Castelo-Branco G, Cramer P, Adameyko I, Linnarsson S, Kharchenko PV.

Nature. 2018 Aug;560(7719):494-498. doi: 10.1038/s41586-018-0414-6. Epub 2018 Aug 8.

29.

Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.

O'Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):648-657.e15. doi: 10.1016/j.clml.2018.06.016. Epub 2018 Jun 28.

30.

Change in Children's Self Confidence and the Use of Defense Mechanisms.

Cramer P.

J Nerv Ment Dis. 2018 Aug;206(8):593-597. doi: 10.1097/NMD.0000000000000848.

PMID:
30020210
31.

Distinct Mechanisms of Transcription Initiation by RNA Polymerases I and II.

Engel C, Neyer S, Cramer P.

Annu Rev Biophys. 2018 May 20;47:425-446. doi: 10.1146/annurev-biophys-070317-033058. Review.

PMID:
29792819
32.

Cryo-EM structure of a mammalian RNA polymerase II elongation complex inhibited by α-amanitin.

Liu X, Farnung L, Wigge C, Cramer P.

J Biol Chem. 2018 May 11;293(19):7189-7194. doi: 10.1074/jbc.RA118.002545. Epub 2018 Mar 17.

33.

CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.

Cramer P, von Tresckow J, Bahlo J, Engelke A, Langerbeins P, Fink AM, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Böttcher S, Eichhorst B, Hallek M.

Future Oncol. 2018 Mar;14(6):499-513. doi: 10.2217/fon-2017-0442. Epub 2018 Feb 21.

34.

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.

Herling CD, Abedpour N, Weiss J, Schmitt A, Jachimowicz RD, Merkel O, Cartolano M, Oberbeck S, Mayer P, Berg V, Thomalla D, Kutsch N, Stiefelhagen M, Cramer P, Wendtner CM, Persigehl T, Saleh A, Altmüller J, Nürnberg P, Pallasch C, Achter V, Lang U, Eichhorst B, Castiglione R, Schäfer SC, Büttner R, Kreuzer KA, Reinhardt HC, Hallek M, Frenzel LP, Peifer M.

Nat Commun. 2018 Feb 20;9(1):727. doi: 10.1038/s41467-018-03170-7.

35.

The Development of Defense Mechanisms During the Latency Period.

Cramer P.

J Nerv Ment Dis. 2018 Apr;206(4):286-289. doi: 10.1097/NMD.0000000000000793.

PMID:
29419639
36.

Aging African green monkeys manifest transcriptional, pathological, and cognitive hallmarks of human Alzheimer's disease.

Cramer PE, Gentzel RC, Tanis KQ, Vardigan J, Wang Y, Connolly B, Manfre P, Lodge K, Renger JJ, Zerbinatti C, Uslaner JM.

Neurobiol Aging. 2018 Apr;64:92-106. doi: 10.1016/j.neurobiolaging.2017.12.011. Epub 2017 Dec 20.

PMID:
29353102
37.

The Effect of Prucalopride on Small Bowel Transit Time in Hospitalized Patients Undergoing Capsule Endoscopy.

Alsahafi M, Cramer P, Chatur N, Donnellan F.

Can J Gastroenterol Hepatol. 2017;2017:2696947. doi: 10.1155/2017/2696947. Epub 2017 Nov 23.

38.

Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study.

Cramer P, Fraser G, Santucci-Silva R, Grosicki S, Dilhuydy MS, Janssens A, Loscertales J, Rule S, Goy A, Traina S, Chan EKH, Diels J, Sengupta N, Mahler M, Salman M, Howes A, Chanan-Khan A.

Leuk Lymphoma. 2018 Sep;59(9):2075-2084. doi: 10.1080/10428194.2017.1416364. Epub 2018 Jan 3.

PMID:
29295653
39.

Acute and Subchronic Toxicity Studies of Aqueous Extract of Desmodium adscendens (Sw) DC.

Quaye O, Cramer P, Ofosuhene M, Okine LKN, Nyarko AK.

J Evid Based Complementary Altern Med. 2017 Oct;22(4):753-759. doi: 10.1177/2156587217736587. Epub 2017 Nov 7.

40.

Structural Basis of Mitochondrial Transcription Initiation.

Hillen HS, Morozov YI, Sarfallah A, Temiakov D, Cramer P.

Cell. 2017 Nov 16;171(5):1072-1081.e10. doi: 10.1016/j.cell.2017.10.036.

41.

Structures of transcription pre-initiation complex with TFIIH and Mediator.

Schilbach S, Hantsche M, Tegunov D, Dienemann C, Wigge C, Urlaub H, Cramer P.

Nature. 2017 Nov 9;551(7679):204-209. doi: 10.1038/nature24282. Epub 2017 Nov 1.

42.

Mechanism of RNA polymerase II stalling by DNA alkylation.

Malvezzi S, Farnung L, Aloisi CMN, Angelov T, Cramer P, Sturla SJ.

Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):12172-12177. doi: 10.1073/pnas.1706592114. Epub 2017 Oct 30.

43.

Mechanism of Transcription Anti-termination in Human Mitochondria.

Hillen HS, Parshin AV, Agaronyan K, Morozov YI, Graber JJ, Chernev A, Schwinghammer K, Urlaub H, Anikin M, Cramer P, Temiakov D.

Cell. 2017 Nov 16;171(5):1082-1093.e13. doi: 10.1016/j.cell.2017.09.035. Epub 2017 Oct 12.

44.

Nucleosome-Chd1 structure and implications for chromatin remodelling.

Farnung L, Vos SM, Wigge C, Cramer P.

Nature. 2017 Oct 26;550(7677):539-542. doi: 10.1038/nature24046. Epub 2017 Oct 11.

45.

CDK9-dependent RNA polymerase II pausing controls transcription initiation.

Gressel S, Schwalb B, Decker TM, Qin W, Leonhardt H, Eick D, Cramer P.

Elife. 2017 Oct 10;6. pii: e29736. doi: 10.7554/eLife.29736.

46.

Structure of a transcribing RNA polymerase II-DSIF complex reveals a multidentate DNA-RNA clamp.

Bernecky C, Plitzko JM, Cramer P.

Nat Struct Mol Biol. 2017 Oct;24(10):809-815. doi: 10.1038/nsmb.3465. Epub 2017 Sep 11.

PMID:
28892040
47.

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.

Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA.

Haematologica. 2017 Oct;102(10):1796-1805. doi: 10.3324/haematol.2017.171041. Epub 2017 Jul 27.

48.

Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.

Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, von Tresckow J, Maurer C, Bergmann M, Seiler T, Lange E, Kneba M, Stilgenbauer S, Döhner H, Kiehl MG, Jäger U, Wendtner CM, Fischer K, Goede V, Hallek M, Eichhorst B, Hopfinger G.

Leukemia. 2017 Oct;31(10):2251-2253. doi: 10.1038/leu.2017.221. Epub 2017 Jul 12. No abstract available.

PMID:
28745332
49.

Childhood Precursors of the Narcissistic Personality.

Cramer P.

J Nerv Ment Dis. 2017 Sep;205(9):679-684. doi: 10.1097/NMD.0000000000000703.

PMID:
28632514
50.

Architecture of the RNA polymerase II-Paf1C-TFIIS transcription elongation complex.

Xu Y, Bernecky C, Lee CT, Maier KC, Schwalb B, Tegunov D, Plitzko JM, Urlaub H, Cramer P.

Nat Commun. 2017 Jun 6;8:15741. doi: 10.1038/ncomms15741.

Supplemental Content

Loading ...
Support Center